(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform. Shares of the company were up 8.5% in afternoon trading. The telehealth firm is following its peers Teladoc and LifeMD in offering Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.

Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused on weight management. The collaboration connects Noom users with Eli Lilly’s pharmacy provider,

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members whose doctors have prescribed FDA-approved medications. Since 2023, Noom has offered branded medications,